Latest News

Immunocore Names David Berman as Head of R&D

OXFORD, England & CONSHOHOCKEN, Pa.–(BUSINESS WIRE)–Immunocore Limited, a leading T Cell Receptor (TCR) biotechnology company focused on delivering first-in-class biological therapies that have the potential to transform lives of people with serious diseases, today names David Berman as its new Head of Research and Development. David joined Immunocore in September 2018 to advance the Company’s lead candidate, IMCgp100, towards commercialisation and progress Immunocore’s growing pipeline of TC

Source link

Related posts

Insufficient sleep mirrored by DNA from blood leukocytes


STAT Plus: Regeneron drug reduces bone growth for patients with ultra-rare skeletal disease


Medical News Today: Exercising before breakfast may be most healthful choice


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy